BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7. [PMID: 12107836 DOI: 10.1038/sj.bjc.6600446] [Cited by in Crossref: 382] [Cited by in F6Publishing: 349] [Article Influence: 19.1] [Reference Citation Analysis]
Number Citing Articles
1 Reni M, Bonetto E, Cordio S, Passoni P, Milandri C, Cereda S, Spreafico A, Galli L, Bordonaro R, Staudacher C, Di Carlo V, Johnson CD. Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III randomized trial. Pancreatology 2006;6:454-63. [DOI: 10.1159/000094563] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
2 Longo V, Brunetti O, Gnoni A, Cascinu S, Gasparini G, Lorusso V, Ribatti D, Silvestris N. Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Oncotarget 2016;7:58649-58. [PMID: 27462915 DOI: 10.18632/oncotarget.10765] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 11.5] [Reference Citation Analysis]
3 Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005;1755:37-69. [PMID: 15907591 DOI: 10.1016/j.bbcan.2005.03.001] [Cited by in Crossref: 75] [Cited by in F6Publishing: 234] [Article Influence: 4.4] [Reference Citation Analysis]
4 Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E. Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer. Ann Surg Oncol 2008;15:3521-31. [DOI: 10.1245/s10434-008-0152-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
5 Moreira AM, Pereira J, Melo S, Fernandes MS, Carneiro P, Seruca R, Figueiredo J. The Extracellular Matrix: An Accomplice in Gastric Cancer Development and Progression. Cells 2020;9:E394. [PMID: 32046329 DOI: 10.3390/cells9020394] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
6 Winer A, Janosky M, Harrison B, Zhong J, Moussai D, Siyah P, Schatz-Siemers N, Zeng J, Adams S, Mignatti P. Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study. Mol Cancer Ther 2016;15:2370-7. [PMID: 27466357 DOI: 10.1158/1535-7163.MCT-16-0194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
7 Spratlin JL, Mackey JR. Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers (Basel) 2010;2:2044-54. [PMID: 24281217 DOI: 10.3390/cancers2042044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
8 Riess H. Antiangiogenic strategies in pancreatic cancer. Recent Results Cancer Res 2008;177:123-9. [PMID: 18084954 DOI: 10.1007/978-3-540-71279-4_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
9 Jafari M, Abbruzzese JL. Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal intergroup pancreatic cancer task force. Surgical Oncology Clinics of North America 2004;13:751-60. [DOI: 10.1016/j.soc.2004.06.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
10 Zhang S, Xie W, Zou Y, Xie S, Zhang J, Yuan W, Ma J, Zhao J, Zheng C, Chen Y, Wang C. First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis. Cancer Manag Res 2018;10:5965-78. [PMID: 30538546 DOI: 10.2147/CMAR.S162980] [Reference Citation Analysis]
11 Whittle MC, Hingorani SR. Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. Cancer J 2017;23:326-32. [PMID: 29189328 DOI: 10.1097/PPO.0000000000000289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer. 2008;99:883-893. [PMID: 19238630 DOI: 10.1038/sj.bjc.6604568] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
13 Liu D, Steins A, Klaassen R, van der Zalm AP, Bennink RJ, van Tienhoven G, Besselink MG, Bijlsma MF, van Laarhoven HWM. Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. Biomedicines 2020;8:E444. [PMID: 33105540 DOI: 10.3390/biomedicines8110444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Taïeb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, Fallik D, Spano JP, Landi B, Lledo G. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol. 2007;18:498-503. [PMID: 17158774 DOI: 10.1093/annonc/mdl427] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
15 Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest 2007;25:594-8. [PMID: 17852117 DOI: 10.1080/07357900701359932] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
16 Erstad DJ, Sojoodi M, Taylor MS, Ghoshal S, Razavi AA, Graham-O'Regan KA, Bardeesy N, Ferrone CR, Lanuti M, Caravan P, Tanabe KK, Fuchs BC. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Dis Model Mech 2018;11:dmm034793. [PMID: 29903803 DOI: 10.1242/dmm.034793] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
17 Kong X, Li L, Li Z, Xie K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 2012;23:343-56. [PMID: 22749856 DOI: 10.1016/j.cytogfr.2012.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
18 Kleger A, Perkhofer L, Seufferlein T. Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol. 2014;25:1260-1270. [PMID: 24631947 DOI: 10.1093/annonc/mdu013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
19 Trevino JG, Gray MJ, Nawrocki ST, Summy JM, Lesslie DP, Evans DB, Sawyer TK, Shakespeare WC, Watowich SS, Chiao PJ. Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis. 2006;9:101-110. [PMID: 16871430 DOI: 10.1007/s10456-006-9038-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
20 Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, Friess H, B??chler MW, Reiter RE, Hines OJ. Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer: . Pancreas 2005;31:119-25. [DOI: 10.1097/01.mpa.0000173459.81193.4d] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 3.9] [Reference Citation Analysis]
21 Lakkakula BVKS, Farran B, Lakkakula S, Peela S, Yarla NS, Bramhachari PV, Kamal MA, Saddala MS, Nagaraju GP. Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles. Seminars in Cancer Biology 2019;56:149-67. [DOI: 10.1016/j.semcancer.2018.09.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
22 Opitz FV, Haeberle L, Daum A, Esposito I. Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia. Cancers 2021;13:6188. [DOI: 10.3390/cancers13246188] [Reference Citation Analysis]
23 Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82. [PMID: 18373843 DOI: 10.1186/11471-2407-8-82] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs 2006;15:1395-410. [PMID: 17040199 DOI: 10.1517/13543784.15.11.1395] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
25 Saad ED, Hoff PM. Molecular-Targeted Agents in Pancreatic Cancer. Cancer Control 2017;11:32-8. [DOI: 10.1177/107327480401100205] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
26 Rocha-Lima CM. New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs. 2008;19:435-446. [PMID: 18418211 DOI: 10.1097/cad.0b013e3282fc9d11] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
27 Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M, Borchert P, Schmuhl E, Linnebacher M, Hinz B. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 2012;26:1535-48. [PMID: 22198381 DOI: 10.1096/fj.11-198184] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 7.4] [Reference Citation Analysis]
28 Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007;56:1134-1152. [PMID: 17625148 DOI: 10.1136/gut.2006.103333] [Cited by in Crossref: 84] [Cited by in F6Publishing: 179] [Article Influence: 5.6] [Reference Citation Analysis]
29 Renouf D, Moore M. Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther 2010;10:529-40. [PMID: 20397918 DOI: 10.1586/era.10.21] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
30 Kota J, Hancock J, Kwon J, Korc M. Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Lett. 2017;391:38-49. [PMID: 28093284 DOI: 10.1016/j.canlet.2016.12.035] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 16.6] [Reference Citation Analysis]
31 Chen L, Zhang M, Luo S. Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies. Tumor Biol 2014;35:11551-8. [DOI: 10.1007/s13277-014-2451-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
32 Yeh C, Bates SE. Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Semin Oncol 2021:S0093-7754(21)00001-4. [PMID: 33712267 DOI: 10.1053/j.seminoncol.2021.01.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Goldstein D, Carroll S, Apte M, Keogh G. Modern management of pancreatic carcinoma. Intern Med J. 2004;34:475-481. [PMID: 15317546 DOI: 10.1111/j.1444-0903.2004.00658.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
34 Chandana S, Babiker HM, Mahadevan D. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs 2018;28:161-77. [DOI: 10.1080/13543784.2019.1557145] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
35 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
36 Tonini G, Pantano F, Vincenzi B, Gabbrielli A, Coppola R, Santini D. Molecular prognostic factors in patients with pancreatic cancer. Expert Opinion on Therapeutic Targets 2007;11:1553-69. [DOI: 10.1517/14728222.11.12.1553] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
37 Jimenez RE, Castillo CF. Tumors of the Pancreas. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 1017-1034.e4. [DOI: 10.1016/b978-1-4160-6189-2.00060-3] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
38 Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology. 2005;128:1606-1625. [PMID: 15887154 DOI: 10.1053/j.gastro.2005.04.001] [Cited by in Crossref: 210] [Cited by in F6Publishing: 204] [Article Influence: 12.4] [Reference Citation Analysis]
39 Kudgus RA, Szabolcs A, Khan JA, Walden CA, Reid JM, Robertson JD, Bhattacharya R, Mukherjee P. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One 2013;8:e57522. [PMID: 23483913 DOI: 10.1371/journal.pone.0057522] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
40 Madden EC, Gorman AM, Logue SE, Samali A. Tumour Cell Secretome in Chemoresistance and Tumour Recurrence. Trends Cancer 2020;6:489-505. [PMID: 32460003 DOI: 10.1016/j.trecan.2020.02.020] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
41 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
42 Tholey R, Sawicki JA, Brody JR. Molecular-Based and Alternative Therapies for Pancreatic Cancer: Looking “Out of the Box”. The Cancer Journal 2012;18:665-73. [DOI: 10.1097/ppo.0b013e3182793ff6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
43 Yalcin S, Dane F, Oksuzoglu B, Ozdemir NY, Isikdogan A, Ozkan M, Demirag GG, Coskun HS, Karabulut B, Evrensel T, Ustaoglu MA, Ozdemir F, Turna H, Yavuzsen T, Aykan F, Sevinc A, Akbulut H, Yuce D, Hayran M, Kilickap S. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. BMC Cancer 2020;20:259. [PMID: 32228512 DOI: 10.1186/s12885-020-06758-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
44 Lee KH, Kim MK, Kim YH, Ryoo BY, Lim HY, Song HS, Kim HK, Lee MA, Im SA, Chang HM, Cho JY, Zang DY, Kim BS, Kim JS. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. Cancer Chemother Pharmacol 2009;64:317-25. [PMID: 19034448 DOI: 10.1007/s00280-008-0873-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
45 Pandey V, Storz P. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. Expert Rev Anticancer Ther 2019;19:473-82. [PMID: 31148495 DOI: 10.1080/14737140.2019.1622417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
46 Van Laethem J, Marechal R. Emerging drugs for the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs 2007;12:301-11. [DOI: 10.1517/14728214.12.2.301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
47 Steins M, Thomas M, Geißler M. Erlotinib. In: Martens UM, editor. Small Molecules in Oncology. Berlin: Springer Berlin Heidelberg; 2010. pp. 21-31. [DOI: 10.1007/978-3-642-01222-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Nieto J, Grossbard ML, Kozuch P. Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty? The Oncol 2008;13:562-76. [DOI: 10.1634/theoncologist.2007-0181] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 5.1] [Reference Citation Analysis]
49 Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011;22:1500-1506. [PMID: 21199884 DOI: 10.1093/annonc/mdq545] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
50 Koikawa K, Ohuchida K, Ando Y, Kibe S, Nakayama H, Takesue S, Endo S, Abe T, Okumura T, Iwamoto C, Moriyama T, Nakata K, Miyasaka Y, Ohtsuka T, Nagai E, Mizumoto K, Hashizume M, Nakamura M. Basement membrane destruction by pancreatic stellate cells leads to local invasion in pancreatic ductal adenocarcinoma. Cancer Letters 2018;425:65-77. [DOI: 10.1016/j.canlet.2018.03.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
51 Wong HH, Lemoine NR. Biological approaches to therapy of pancreatic cancer. Pancreatology. 2008;8:431-461. [PMID: 18724071 DOI: 10.1159/000151536] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
52 Gao C, Wu X, Yan Y, Meng L, Shan D, Li Y, Han B. Sensitization of Radiation or Gemcitabine-Based Chemoradiation Therapeutic Effect by Nimotuzumab in Pancreatic Cancer Cells. Technol Cancer Res Treat 2016;15:446-52. [PMID: 25987640 DOI: 10.1177/1533034615585209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
53 Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther 2010;3:111-27. [PMID: 20856847 DOI: 10.2147/ott.s7203] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
54 Nakano Y, Kitago M, Shinoda M, Abe Y, Yagi H, Hibi T, Takeuchi A, Aiura K, Itano O, Kitagawa Y. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med 2017;6:2278-86. [PMID: 28925039 DOI: 10.1002/cam4.1178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
55 Schwarz RE, Konduri S, Awasthi N, Cafasso D, Schwarz MA. An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. Surgery 2009;146:241-9. [DOI: 10.1016/j.surg.2009.04.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
56 Boedefeld WM, Bland KI, Heslin MJ. Recent Insights Into Angiogenesis, Apoptosis, Invasion, and Metastasis in Colorectal Carcinoma. Ann Surg Oncol 2003;10:839-51. [DOI: 10.1245/aso.2003.02.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
57 Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D; Cancer and Leukemia Group B. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 2012;43:205-17. [PMID: 22104618 DOI: 10.1016/j.jpainsymman.2011.09.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
58 Chen J, Chen L, Yu J, Xu Y, Wang X, Zeng Z, Liu N, Xu F, Yang S. Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities. Mol Med Rep 2019;19:477-89. [PMID: 30431091 DOI: 10.3892/mmr.2018.9638] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Ambe C, Fulp W, Springett G, Hoffe S, Mahipal A. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. J Gastrointest Canc 2015;46:284-90. [DOI: 10.1007/s12029-015-9734-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
60 Ben-Josef E, Lawrence TS. Chemoradiotherapy for unresectable pancreatic cancer. Int J Clin Oncol 2008;13:121-6. [PMID: 18463955 DOI: 10.1007/s10147-007-0763-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
61 Warsame R, Grothey A. Treatment options for advanced pancreatic cancer: a review. Expert Rev Anticancer Ther 2012;12:1327-36. [PMID: 23176620 DOI: 10.1586/era.12.115] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
62 Hilmi M, Nicolle R, Bousquet C, Neuzillet C. Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion. Cancers (Basel) 2020;12:E2969. [PMID: 33066357 DOI: 10.3390/cancers12102969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
63 Li K, Tay FR, Yiu CKY. The past, present and future perspectives of matrix metalloproteinase inhibitors. Pharmacology & Therapeutics 2020;207:107465. [DOI: 10.1016/j.pharmthera.2019.107465] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 17.5] [Reference Citation Analysis]
64 Lewis AR, Pihlak R, McNamara MG. The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Curr Probl Cancer 2018;42:26-39. [PMID: 29631711 DOI: 10.1016/j.currproblcancer.2018.01.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
65 Maréchal R, Demols A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethem J. Prognostic Factors and Prognostic Index for Chemonaïve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer. Oncology 2007;73:41-51. [DOI: 10.1159/000120627] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
66 Bayraktar S, Rocha Lima CM. Emerging cell-cycle inhibitors for pancreatic cancer therapy. Expert Opinion on Emerging Drugs 2012;17:571-82. [DOI: 10.1517/14728214.2012.739606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
67 Nielsen MFB, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 2016; 22(9): 2678-2700 [PMID: 26973408 DOI: 10.3748/wjg.v22.i9.2678] [Cited by in CrossRef: 127] [Cited by in F6Publishing: 112] [Article Influence: 21.2] [Reference Citation Analysis]
68 Rubinson DA, Wolpin BM. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:761-76. [PMID: 26226909 DOI: 10.1016/j.hoc.2015.04.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
69 Cao Y, Wu L, Tan A, Liu L, Liao C, Gao F. Meta-Analysis of Randomized Trials: Evaluation of Benefit of Gemcitabine-Based Molecular Targeted Therapy for Inoperable Pancreatic Cancer. Pancreas 2010;39:253-5. [DOI: 10.1097/mpa.0b013e3181bdc6b8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
70 Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2009;:CD002093. [PMID: 19821291 DOI: 10.1002/14651858.CD002093.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
71 Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438. [PMID: 15084616 DOI: 10.1200/jco.2004.10.112] [Cited by in Crossref: 575] [Cited by in F6Publishing: 213] [Article Influence: 31.9] [Reference Citation Analysis]
72 Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002;2:657-672. [PMID: 12209155 DOI: 10.1038/nrc884] [Cited by in Crossref: 915] [Cited by in F6Publishing: 848] [Article Influence: 45.8] [Reference Citation Analysis]
73 Neuzillet C, Rousseau B, Kocher H, Bourget P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. Pharmacol Ther. 2017;174:145-172. [PMID: 28223233 DOI: 10.1016/j.pharmthera.2017.02.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
74 Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol. 2005;23:1295-1311. [PMID: 15718328 DOI: 10.1200/jco.2005.10.022] [Cited by in Crossref: 150] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
75 Saif MW. Erlotinib: the first biologic in the management of pancreatic cancer. Expert Opin Pharmacother 2008;9:1595-607. [PMID: 18518788 DOI: 10.1517/14656566.9.9.1595] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
76 Au M, Emeto TI, Power J, Vangaveti VN, Lai HC. Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines 2016;4:E20. [PMID: 28536387 DOI: 10.3390/biomedicines4030020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
77 Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Expert Opin Ther Targets 2003;7:385-97. [PMID: 12783574 DOI: 10.1517/14728222.7.3.385] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
78 Li Q, Yuan Z, Yan H, Wen Z, Zhang R, Cao B. Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer. Clin Ther 2014;36:1054-63. [PMID: 24986485 DOI: 10.1016/j.clinthera.2014.05.066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
79 Awasthi N, Schwarz MA, Schwarz RE. Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer. HPB (Oxford) 2009;11:600-5. [PMID: 20495713 DOI: 10.1111/j.1477-2574.2009.00109.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
80 Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, Neesse A. Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews 2020;100:1707-51. [DOI: 10.1152/physrev.00042.2019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
81 Planting A, van der Gaast A, Schöffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J. A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2005;55:136-42. [DOI: 10.1007/s00280-004-0905-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
82 Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E. A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer. Drug Resist Updat 2017;31:43-51. [PMID: 28867243 DOI: 10.1016/j.drup.2017.07.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
83 Awasthi N, Schwarz MA, Schwarz RE. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB (Oxford) 2011;13:597-604. [PMID: 21843259 DOI: 10.1111/j.1477-2574.2011.00333.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
84 Boeck S, Heinemann V. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol 2008;4:41-50. [PMID: 18240999 DOI: 10.2217/14796694.4.1.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ogura Y, Tajrishi MM, Sato S, Hindi SM, Kumar A. Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy. Front Cell Dev Biol 2014;2:11. [PMID: 25364719 DOI: 10.3389/fcell.2014.00011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
86 Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016; 8(1): 55-66 [PMID: 26798437 DOI: 10.4251/wjgo.v8.i1.55] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
87 Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2013;7:33-43. [PMID: 24379681 DOI: 10.2147/ott.s38111] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
88 Lockhart AC, Rothenberg ML, Berlin JD. Treatment for Pancreatic Cancer: Current Therapy and Continued Progress. Gastroenterology 2005;128:1642-54. [DOI: 10.1053/j.gastro.2005.03.039] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 6.0] [Reference Citation Analysis]
89 Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ. Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int. 2011;2011:620601. [PMID: 21512581 DOI: 10.4061/2011/620601] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
90 Quesada AR, Muñoz-Chápuli R, Medina MA. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 2006;26:483-530. [PMID: 16652370 DOI: 10.1002/med.20059] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 6.8] [Reference Citation Analysis]
91 van der Jagt MF, Wobbes T, Strobbe LJ, Sweep FC, Span PN. Metalloproteinases and their regulators in colorectal cancer: MP Regulators in Colorectal Cancer. J Surg Oncol 2010;101:259-69. [DOI: 10.1002/jso.21462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
92 Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007;18 Suppl 7:vii1-vii10. [PMID: 17600091 DOI: 10.1093/annonc/mdm210] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
93 Miller KD. Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? Breast Cancer Res 2004;6:128-32. [PMID: 15084233 DOI: 10.1186/bcr782] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
94 Cho JH. [Recent update of molecular targeted therapy in pancreatic cancer]. Korean J Gastroenterol 2013;61:147-54. [PMID: 23575233 DOI: 10.4166/kjg.2013.61.3.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
95 Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz AA, Mansour AM, Huo L, Ozpolat B. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion. J Cell Mol Med 2014;18:2235-51. [PMID: 25215932 DOI: 10.1111/jcmm.12361] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
96 de Castro Junior G, Puglisi F, de Azambuja E, El Saghir NS, Awada A. Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol 2006;59:40-50. [PMID: 16600618 DOI: 10.1016/j.critrevonc.2006.02.007] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
97 Jackson AS, Jain P, Watkins GR, Whitfield GA, Green MM, Valle J, Taylor MB, Dickinson C, Price PM, Saleem A. Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. Clin Oncol (R Coll Radiol) 2010;22:570-7. [PMID: 20650619 DOI: 10.1016/j.clon.2010.06.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
98 Okumura T, Ohuchida K, Sada M, Abe T, Endo S, Koikawa K, Iwamoto C, Miura D, Mizuuchi Y, Moriyama T, Nakata K, Miyasaka Y, Manabe T, Ohtsuka T, Nagai E, Mizumoto K, Oda Y, Hashizume M, Nakamura M. Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancreatic cancer cells. Oncotarget 2017;8:18280-95. [PMID: 28407685 DOI: 10.18632/oncotarget.15430] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
99 Winer A, Adams S, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther 2018;17:1147-55. [PMID: 29735645 DOI: 10.1158/1535-7163.MCT-17-0646] [Cited by in Crossref: 182] [Cited by in F6Publishing: 127] [Article Influence: 45.5] [Reference Citation Analysis]
100 Chetty C, Rao JS, Lakka SS. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma. Pharmacogenomics 2011;12:535-46. [PMID: 21521025 DOI: 10.2217/pgs.10.207] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
101 Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT)., Association Française de Chirurgie (AFC). Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018;50:1257-71. [PMID: 30219670 DOI: 10.1016/j.dld.2018.08.008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
102 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 504] [Article Influence: 43.0] [Reference Citation Analysis]
103 Soto JL, Barbera VM, Saceda M, Carrato A. Molecular biology of exocrine pancreatic cancer. Clin Transl Oncol 2006;8:306-12. [PMID: 16760004 DOI: 10.1007/s12094-006-0175-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
104 Philip PA. Novel targets for pancreatic cancer therapy. Surg Oncol Clin N Am 2010;19:419-29. [PMID: 20159523 DOI: 10.1016/j.soc.2009.11.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
105 Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008;27:495-522. [PMID: 18427734 DOI: 10.1007/s10555-008-9134-y] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
106 Ormanns S, Haas M, Baechmann S, Altendorf-Hofmann A, Remold A, Quietzsch D, Clemens MR, Bentz M, Geissler M, Lambertz H, Kruger S, Kirchner T, Heinemann V, Boeck S. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. Br J Cancer. 2016;115:1520-1529. [PMID: 27802454 DOI: 10.1038/bjc.2016.355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
107 Xiong HQ, Abbruzzese JL. Adjuvant therapy for pancreatic cancer: current status and future directions. Surg Oncol Clin N Am 2004;13:737-49, xi. [PMID: 15350945 DOI: 10.1016/j.soc.2004.06.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Létourneau R, Bajetta E, Pithavala Y, Bycott P. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008;371:2101-2108. [PMID: 18514303 DOI: 10.1016/s0140-6736(08)60661-3] [Cited by in Crossref: 189] [Cited by in F6Publishing: 75] [Article Influence: 13.5] [Reference Citation Analysis]
109 Eltawil KM, Renfrew PD, Molinari M. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB (Oxford) 2012;14:260-8. [PMID: 22404265 DOI: 10.1111/j.1477-2574.2012.00441.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
110 Cheema AR, O’reilly EM. Management of Metastatic Pancreatic Adenocarcinoma. Surgical Clinics of North America 2016;96:1391-414. [DOI: 10.1016/j.suc.2016.07.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
111 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med 2013;11:291. [PMID: 24237633 DOI: 10.1186/1479-5876-11-291] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
113 Páez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am. 2012;41:189-209. [PMID: 22341258 DOI: 10.1016/j.gtc.2011.12.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
114 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
115 Chaussain-miller C, Fioretti F, Goldberg M, Menashi S. The Role of Matrix Metalloproteinases (MMPs) in Human Caries. J Dent Res 2006;85:22-32. [DOI: 10.1177/154405910608500104] [Cited by in Crossref: 225] [Cited by in F6Publishing: 196] [Article Influence: 37.5] [Reference Citation Analysis]
116 Wolff RA. Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy. Cancer J 2007;13:175-84. [PMID: 17620767 DOI: 10.1097/PPO.0b013e318074e6c3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
117 Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
118 Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs 2012;30:1531-9. [PMID: 21670972 DOI: 10.1007/s10637-011-9697-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
119 Mandalà M, Moro C, Labianca R. Venous Thromboembolism and Pancreatic Cancer: Incidence, Pathogenesis and Clinical Implications. Onkologie 2008;31:129-35. [DOI: 10.1159/000113533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
120 Schnittert J, Bansal R, Prakash J. Targeting Pancreatic Stellate Cells in Cancer. Trends Cancer 2019;5:128-42. [PMID: 30755305 DOI: 10.1016/j.trecan.2019.01.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
121 Cartwright T, Richards DA, Boehm KA. Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 2008;15:308-13. [PMID: 18813198 DOI: 10.1177/107327480801500405] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
122 Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer P. Locally advanced pancreatic cancer: current therapeutic approach. Oncologist. 2006;11:612-623. [PMID: 16794240 DOI: 10.1634/theoncologist.11-6-612] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
123 Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
124 Freidlin B, Korn EL. Monitoring for lack of benefit: a critical component of a randomized clinical trial. J Clin Oncol 2009;27:629-33. [PMID: 19064977 DOI: 10.1200/JCO.2008.17.8905] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
125 Jones VA, Patel PM, Gibson FT, Cordova A, Amber KT. The Role of Collagen XVII in Cancer: Squamous Cell Carcinoma and Beyond. Front Oncol 2020;10:352. [PMID: 32266137 DOI: 10.3389/fonc.2020.00352] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
126 Trouilloud I, Dubreuil O, Boussaha T, Lepère C, Landi B, Zaanan A, Bachet JB, Taieb J. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol 2011;35:364-74. [PMID: 21435966 DOI: 10.1016/j.clinre.2011.02.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
127 Bendersky V, Yang Y, Brennan TV. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545. Adv Exp Med Biol 2020;1221:461-70. [PMID: 32274722 DOI: 10.1007/978-3-030-34521-1_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
128 Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials? World J Gastroenterol 2013; 19(8): 1173-1181 [PMID: 23482354 DOI: 10.3748/wjg.v19.i8.1173] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
129 Lièvre A, Landi B, Mitry E, Taïeb J. Les antiangiogéniques en oncologie digestive. Gastroentérologie Clinique et Biologique 2008;32:504-20. [DOI: 10.1016/j.gcb.2008.01.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
130 Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L, Guo J. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?Front Oncol. 2020;10:576399. [PMID: 33178608 DOI: 10.3389/fonc.2020.576399] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
131 Gasparini G, Longo R, Torino F, Gattuso D, Morabito A, Toffoli G. Is tailored therapy feasible in oncology? Critical Reviews in Oncology/Hematology 2006;57:79-101. [DOI: 10.1016/j.critrevonc.2005.07.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
132 Kumar A, Bhatnagar S, Kumar A. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am J Pathol 2010;177:248-60. [PMID: 20472898 DOI: 10.2353/ajpath.2010.091176] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
133 Liu X, Li Z, Wang Y. Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Adv Biol (Weinh) 2021;5:e1900236. [PMID: 33729700 DOI: 10.1002/adbi.201900236] [Reference Citation Analysis]
134 Sgouros J, Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncologica 2009;47:337-46. [DOI: 10.1080/02841860701687267] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
135 Yokoyama Y, Nimura Y, Nagino M. Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies. Surg Today. 2009;39:466-475. [PMID: 19468801 DOI: 10.1007/s00595-008-3904-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
136 Das S, Amin SA, Jha T. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies. Eur J Med Chem 2021;223:113623. [PMID: 34157437 DOI: 10.1016/j.ejmech.2021.113623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Burris H, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist. 2008;13:289-298. [PMID: 18378539 DOI: 10.1634/theoncologist.2007-0134] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
138 Rothenberg ML, Carbone DP, Johnson DH. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 2003;3:303-9. [DOI: 10.1038/nrc1047] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 5.4] [Reference Citation Analysis]
139 Iovanna J, Mallmann MC, Gonçalves A, Turrini O, Dagorn JC. Current knowledge on pancreatic cancer. Front Oncol. 2012;2:6. [PMID: 22655256 DOI: 10.3389/fonc.2012.00006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
140 Sirohi B, Singh A, Dawood S, Shrikhande SV. Advances in chemotherapy for pancreatic cancer. Indian J Surg Oncol 2015;6:47-56. [PMID: 25937764 DOI: 10.1007/s13193-014-0371-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
141 Steins M, Thomas M, Geissler M. Erlotinib. Recent Results Cancer Res 2014;201:109-23. [PMID: 24756788 DOI: 10.1007/978-3-642-54490-3_6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
142 Chiu JW, Wong H, Leung R, Pang R, Cheung TT, Fan ST, Poon R, Yau T. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist 2014;19:937-50. [PMID: 25117068 DOI: 10.1634/theoncologist.2012-0131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
143 Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008;26:3695-3701. [PMID: 18669454 DOI: 10.1200/jco.2007.15.6240] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
144 Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82. [PMID: 18373843 DOI: 10.1186/1471-2407-8-82] [Cited by in Crossref: 280] [Cited by in F6Publishing: 265] [Article Influence: 20.0] [Reference Citation Analysis]
145 Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas 2017;46:143-50. [PMID: 28085753 DOI: 10.1097/MPA.0000000000000753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
146 Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. Is metastatic pancreatic cancer an untargetable malignancy? World J Gastrointest Oncol 2016; 8(3): 297-304 [PMID: 26989465 DOI: 10.4251/wjgo.v8.i3.297] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
147 Zhan HX, Zhou B, Cheng YG, Xu JW, Wang L, Zhang GY, Hu SY. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. Cancer Lett. 2017;392:83-93. [PMID: 28189533 DOI: 10.1016/j.canlet.2017.01.041] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 10.6] [Reference Citation Analysis]
148 Faris JE, Arnott J, Zheng H, Ryan DP, Abrams TA, Blaszkowsky LS, Clark JW, Enzinger PC, Hezel AF, Ng K, Wolpin BM, Kwak EL. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs 2012;30:1614-20. [PMID: 21800081 DOI: 10.1007/s10637-011-9708-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
149 Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25:2607-2615. [PMID: 17577041 DOI: 10.1200/jco.2006.09.2551] [Cited by in Crossref: 277] [Cited by in F6Publishing: 111] [Article Influence: 18.5] [Reference Citation Analysis]
150 Buttery RC, Rintoul RC, Sethi T. Small cell lung cancer: the importance of the extracellular matrix. The International Journal of Biochemistry & Cell Biology 2004;36:1154-60. [DOI: 10.1016/s1357-2725(03)00261-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
151 Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opinion on Pharmacotherapy 2007;8:2719-27. [DOI: 10.1517/14656566.8.16.2719] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
152 Wenz F, Tiefenbacher U, Fuss M, Lohr F, Löhr M. Should patients with locally advanced, non-metastatic carcinoma of the pancreas be irradiated? Pancreatology 2003;3:359-66. [DOI: 10.1159/000073650] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
153 Rutland CS, Cockcroft JM, Lothion-Roy J, Harris AE, Jeyapalan JN, Simpson S, Alibhai A, Bailey C, Ballard-Reisch AC, Rizvanov AA, Dunning MD, de Brot S, Mongan NP. Immunohistochemical Characterisation of GLUT1, MMP3 and NRF2 in Osteosarcoma. Front Vet Sci 2021;8:704598. [PMID: 34414229 DOI: 10.3389/fvets.2021.704598] [Reference Citation Analysis]
154 Tong M, Wang J, Zhang H, Xing H, Wang Y, Fang Y, Pan H, Li D. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials. J Cancer 2019;10:968-78. [PMID: 30854103 DOI: 10.7150/jca.26672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
155 Pierantoni C, Pagliacci A, Scartozzi M, Berardi R, Bianconi M, Cascinu S. Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol. 2008;67:27-38. [PMID: 18356073 DOI: 10.1016/j.critrevonc.2008.01.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
156 Miller KD, Dul CL. Breast cancer: the role of angiogenesis and antiangiogenic therapy. Hematology/Oncology Clinics of North America 2004;18:1071-86. [DOI: 10.1016/j.hoc.2004.06.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
157 Yu J, He Z, He X, Luo Z, Lian L, Wu B, Lan P, Chen H. Comprehensive Analysis of the Expression and Prognosis for MMPs in Human Colorectal Cancer. Front Oncol 2021;11:771099. [PMID: 34804973 DOI: 10.3389/fonc.2021.771099] [Reference Citation Analysis]
158 Seicean A, Petrusel L, Seicean R. New targeted therapies in pancreatic cancer. World J Gastroenterol 2015; 21(20): 6127-6145 [PMID: 26034349 DOI: 10.3748/wjg.v21.i20.6127] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
159 Liang M, Wang J, Wu C, Wu M, Hu J, Dai J, Ruan H, Xiong S, Dong C. Targeting matrix metalloproteinase MMP3 greatly enhances oncolytic virus mediated tumor therapy. Transl Oncol 2021;14:101221. [PMID: 34530193 DOI: 10.1016/j.tranon.2021.101221] [Reference Citation Analysis]
160 Aghlara-Fotovat S, Nash A, Kim B, Krencik R, Veiseh O. Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies. Drug Deliv Transl Res 2021. [PMID: 34176099 DOI: 10.1007/s13346-021-01018-0] [Reference Citation Analysis]
161 Schoppmeyer K, Mössner J. [Best supportive care of pancreatic carcinoma]. Internist (Berl) 2004;45:769-76. [PMID: 15160243 DOI: 10.1007/s00108-004-1222-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
162 Barati Bagherabad M, Afzaljavan F, ShahidSales S, Hassanian SM, Avan A. Targeted therapies in pancreatic cancer: Promises and failures. J Cell Biochem. 2019;120:2726-2741. [PMID: 28703890 DOI: 10.1002/jcb.26284] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
163 Espinosa E, Zamora P, Feliu J, González Barón M. Classification of anticancer drugs—a new system based on therapeutic targets. Cancer Treatment Reviews 2003;29:515-23. [DOI: 10.1016/s0305-7372(03)00116-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
164 Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2010;65:527-536. [PMID: 19578850 DOI: 10.1007/s00280-009-1059-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
165 McNally LR, Welch DR, Beck BH, Stafford LJ, Long JW, Sellers JC, Huang ZQ, Grizzle WE, Stockard CR, Nash KT, Buchsbaum DJ. KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clin Exp Metastasis 2010;27:591-600. [PMID: 20844932 DOI: 10.1007/s10585-010-9349-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
166 Cox TR. The matrix in cancer. Nat Rev Cancer 2021;21:217-38. [PMID: 33589810 DOI: 10.1038/s41568-020-00329-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
167 Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006;107:676-85. [DOI: 10.1002/cncr.22036] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
168 Campen CJ, Dragovich T, Baker AF. Management strategies in pancreatic cancer. Am J Health Syst Pharm 2011;68:573-84. [PMID: 21411798 DOI: 10.2146/ajhp100254] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
169 Starling N, Neoptolemos J, Cunningham D. Role of erlotinib in the management of pancreatic cancer. Ther Clin Risk Manag 2006;2:435-45. [PMID: 18360654 DOI: 10.2147/tcrm.2006.2.4.435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
170 Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004;22:4683-90. [PMID: 15570070 DOI: 10.1200/JCO.2004.08.054] [Cited by in Crossref: 144] [Cited by in F6Publishing: 71] [Article Influence: 8.5] [Reference Citation Analysis]
171 Lin HJ, Lin J. Seed-in-Soil: Pancreatic Cancer Influenced by Tumor Microenvironment. Cancers (Basel) 2017;9:E93. [PMID: 28753978 DOI: 10.3390/cancers9070093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
172 Slapak EJ, Duitman J, Tekin C, Bijlsma MF, Spek CA. Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression? Biology (Basel) 2020;9:E80. [PMID: 32325664 DOI: 10.3390/biology9040080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
173 Sjoquist KM, Chin VT, Chantrill LA, O’Connor C, Hemmings C, Chang DK, Chou A, Pajic M, Johns AL, Nagrial AM, Biankin AV, Yip D. Personalising pancreas cancer treatment: When tissue is the issue. World J Gastroenterol 2014; 20(24): 7849-7863 [PMID: 24976722 DOI: 10.3748/wjg.v20.i24.7849] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
174 Longo R, Cacciamani F, Naso G, Gasparini G. Pancreatic cancer: from molecular signature to target therapy. Crit Rev Oncol Hematol 2008;68:197-211. [PMID: 18436450 DOI: 10.1016/j.critrevonc.2008.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
175 Pelzer U. First-Line Chemotherapy in Advanced Pancreatic Cancer. Pancreatic Cancer. Berlin: Springer Berlin Heidelberg; 2008. pp. 57-60. [DOI: 10.1007/978-3-540-71279-4_7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
176 Wall L, Talbot DC, Bradbury P, Jodrell DI. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer 2004;90:800-4. [PMID: 14970856 DOI: 10.1038/sj.bjc.6601594] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
177 Xie C, Albulescu LO, Bittenbinder MA, Somsen GW, Vonk FJ, Casewell NR, Kool J. Neutralizing Effects of Small Molecule Inhibitors and Metal Chelators on Coagulopathic Viperinae Snake Venom Toxins. Biomedicines 2020;8:E297. [PMID: 32825484 DOI: 10.3390/biomedicines8090297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
178 Galaup A, Germain S. Les anticorps anti-PlGF: Un nouvel outil thérapeutique anti-angiogénique ? Med Sci (Paris) 2008;24:459-62. [DOI: 10.1051/medsci/2008245459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
179 Malgerud L, Lindberg J, Wirta V, Gustafsson-Liljefors M, Karimi M, Moro CF, Stecker K, Picker A, Huelsewig C, Stein M, Bohnert R, Del Chiaro M, Haas SL, Heuchel RL, Permert J, Maeurer MJ, Brock S, Verbeke CS, Engstrand L, Jackson DB, Grönberg H, Löhr JM. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Mol Oncol 2017;11:1413-29. [PMID: 28675654 DOI: 10.1002/1878-0261.12108] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
180 Kimple RJ, Russo S, Monjazeb A, Blackstock AW. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther 2012;12:469-80. [PMID: 22500684 DOI: 10.1586/era.12.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
181 Jacob DA, Bahra M, Langrehr JM, Boas-Knoop S, Stefaniak R, Davis J, Schumacher G, Lippert S, Neumann UP. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J Gastroenterol Hepatol. 2007;22:738-748. [PMID: 17444865 DOI: 10.1111/j.1440-1746.2006.04496.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 26] [Article Influence: 0.5] [Reference Citation Analysis]
182 Hilbig A, Oettle H. Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Rev Anticancer Ther 2008;8:511-23. [PMID: 18402518 DOI: 10.1586/14737140.8.4.511] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
183 Bayraktar S, Rocha-lima CM. Advanced or Metastatic Pancreatic Cancer: Molecular Targeted Therapies: S. B AYRAKTAR AND C. M. R OCHA -L IMA : A DVANCED OR M ETASTATIC P ANCREATIC C ANCER. Mt Sinai J Med 2010;77:606-19. [DOI: 10.1002/msj.20217] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
184 Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6:227-239. [PMID: 16498445 DOI: 10.1038/nrc1821] [Cited by in Crossref: 879] [Cited by in F6Publishing: 822] [Article Influence: 54.9] [Reference Citation Analysis]
185 Das N, Benko C, Gill SE, Dufour A. The Pharmacological TAILS of Matrix Metalloproteinases and Their Inhibitors. Pharmaceuticals (Basel) 2020;14:31. [PMID: 33396445 DOI: 10.3390/ph14010031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
186 Spratlin JL, Chu Q, Koski S, King K, Mulder K. Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol 2011; 2(3): 135-149 [PMID: 21611088 DOI: 10.5306/wjco.v2.i3.135] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
187 Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S. 5-fluorouracil/Leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology. 2011;80:301-306. [PMID: 21778770 DOI: 10.1159/000329803] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]
188 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
189 Bausch D, Pausch T, Krauss T, Hopt UT, Fernandez-del-Castillo C, Warshaw AL, Thayer SP, Keck T. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis. 2011;14:235-243. [PMID: 21442180 DOI: 10.1007/s10456-011-9207-3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 7.0] [Reference Citation Analysis]
190 Overall CM, Dean RA. Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev 2006;25:69-75. [DOI: 10.1007/s10555-006-7890-0] [Cited by in Crossref: 159] [Cited by in F6Publishing: 143] [Article Influence: 9.9] [Reference Citation Analysis]
191 Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017;18:E909. [PMID: 28445400 DOI: 10.3390/ijms18050909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
192 Napoli S, Scuderi C, Gattuso G, Bella VD, Candido S, Basile MS, Libra M, Falzone L. Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma. Cells 2020;9:E1151. [PMID: 32392801 DOI: 10.3390/cells9051151] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
193 Albo D, Farrow B, Berger DH. Translation of Recent Advances and Discoveries in Molecular Biology and Immunology in the Diagnosis and Treatment of Pancreatic Cancer. Surgical Oncology Clinics of North America 2008;17:357-76. [DOI: 10.1016/j.soc.2007.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
194 Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol 2020;17:527-40. [PMID: 32398706 DOI: 10.1038/s41571-020-0363-5] [Cited by in Crossref: 82] [Cited by in F6Publishing: 97] [Article Influence: 41.0] [Reference Citation Analysis]
195 Neesse A, Algül H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64:1476-1484. [PMID: 25994217 DOI: 10.1136/gutjnl-2015-309304] [Cited by in Crossref: 281] [Cited by in F6Publishing: 275] [Article Influence: 40.1] [Reference Citation Analysis]
196 Mahalingam D, Kelly KR, Swords RT, Carew J, Nawrocki ST, Giles FJ. Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs 2009;14:311-28. [PMID: 19466902 DOI: 10.1517/14728210902972502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
197 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 198] [Article Influence: 42.0] [Reference Citation Analysis]
198 Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, Yamaue H. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010;101:433-439. [PMID: 19930156 DOI: 10.1111/j.1349-7006.2009.01416.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
199 Kim EJ, Semrad TJ, Bold RJ. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs. 2015;24:781-794. [PMID: 25809274 DOI: 10.1517/13543784.2015.1026963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
200 Labianca R, Berardi E, Malugani F. Challenges in the treatment of gastrointestinal tumours. Annals of Oncology 2006;17:v137-41. [DOI: 10.1093/annonc/mdj969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
201 Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell’Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer. 2006;94:785-791. [PMID: 16508631 DOI: 10.1038/sj.bjc.6603026] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.4] [Reference Citation Analysis]
202 Cinar P, Tempero MA. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J 2012;18:653-64. [PMID: 23187854 DOI: 10.1097/PPO.0b013e3182758985] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
203 Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60. [PMID: 29508762 DOI: 10.1016/S1470-2045(18)30098-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
204 Papadatos-Pastos D, Thillai K, Rabbie R, Ross P, Sarker D. FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer. Expert Rev Anticancer Ther. 2014;14:1115-1125. [PMID: 25204327 DOI: 10.1586/14737140.2014.957188] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
205 Chua YJ, Cunningham D. Chemotherapy for advanced pancreatic cancer. Best Practice & Research Clinical Gastroenterology 2006;20:327-48. [DOI: 10.1016/j.bpg.2005.10.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
206 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets 2012;13:811-28. [PMID: 22458528 DOI: 10.2174/138945012800564068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
207 Abramson MA, Swanson EW, Whang EE. Surgical resection versus palliative chemoradiotherapy for the management of pancreatic cancer with local venous invasion: a decision analysis. J Gastrointest Surg. 2009;13:26-34. [PMID: 18946644 DOI: 10.1007/s11605-008-0648-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
208 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
209 Ducreux M, Boige V, Malka D. Treatment of advanced pancreatic cancer. Semin Oncol 2007;34:S25-30. [PMID: 17449349 DOI: 10.1053/j.seminoncol.2007.01.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
210 Oettle H, Moser L, Hilbig A, Budach V. Multimodale palliative Behandlung des Pankreaskarzinoms. Onkologe 2004;10:1310-9. [DOI: 10.1007/s00761-004-0799-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
211 Heumann T, Azad N. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance. Cancer Metastasis Rev 2021;40:837-62. [PMID: 34591243 DOI: 10.1007/s10555-021-09981-3] [Reference Citation Analysis]
212 Karelia DN, Kim S, K Pandey M, Plano D, Amin S, Lu J, Sharma AK. Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity. Int J Mol Sci 2021;22:4966. [PMID: 34067020 DOI: 10.3390/ijms22094966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol. 2004;5:541-549. [PMID: 15337483 DOI: 10.1016/S1470-2045(04)01565-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
214 Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial. Oncotarget 2015;6:12796-808. [PMID: 25918250 DOI: 10.18632/oncotarget.3473] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
215 Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F, Giannarelli D. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 2007;110:525-33. [PMID: 17577216 DOI: 10.1002/cncr.22809] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 4.5] [Reference Citation Analysis]
216 Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W;  National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. [PMID: 17452677 DOI: 10.1200/jco.2006.07.9525] [Cited by in Crossref: 2461] [Cited by in F6Publishing: 1262] [Article Influence: 164.1] [Reference Citation Analysis]
217 Van Cutsem E, Verslype C, Grusenmeyer PA. Lessons Learned in the Management of Advanced Pancreatic Cancer. JCO 2007;25:1949-52. [DOI: 10.1200/jco.2006.09.4664] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
218 Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Oncol Rep 2004;6:199-206. [PMID: 15066231 DOI: 10.1007/s11912-004-0050-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
219 Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L;  National Cancer Institute of Canada Clinical Trials Group. Comparison of gemcitabine vs the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3296-3302. [PMID: 12947065 DOI: 10.1200/jco.2003.02.098] [Cited by in Crossref: 268] [Cited by in F6Publishing: 104] [Article Influence: 14.1] [Reference Citation Analysis]
220 Knapinska AM, Estrada CA, Fields GB. The Roles of Matrix Metalloproteinases in Pancreatic Cancer. Prog Mol Biol Transl Sci 2017;148:339-54. [PMID: 28662827 DOI: 10.1016/bs.pmbts.2017.03.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
221 Ogata Y, Matono K, Nakajima M, Sasatomi T, Mizobe T, Nagase H, Shirouzu K. Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat. Int J Cancer 2006;118:215-21. [DOI: 10.1002/ijc.21285] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
222 Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol. 2005;23:9250-9256. [PMID: 16361622 DOI: 10.1200/jco.2005.02.1980] [Cited by in Crossref: 33] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
223 Azmi AS, Philip PA, Zafar SF, Sarkar FH, Mohammad RM. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin Ther Targets 2010;14:611-20. [PMID: 20426700 DOI: 10.1517/14728222.2010.487066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
224 Ko AH. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol. 2007;34:354-364. [PMID: 17674964 DOI: 10.1053/j.seminoncol.2007.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
225 Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Papadimitriou CA, Dimopoulos MA, Filipits M, Bartsch R. Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. Pancreas. 2013;42:760-773. [PMID: 23774698 DOI: 10.1097/mpa.0b013e31827aedef] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
226 Xie DR, Liang HL, Wang Y, Guo SS, Yang Q. Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 2006; 12(43): 6973-6981 [PMID: 17109519 DOI: 10.3748/wjg.v12.i43.6973] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
227 El-Zahaby SA, Elnaggar YSR, Abdallah OY. Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art. J Control Release 2019;293:21-35. [PMID: 30445002 DOI: 10.1016/j.jconrel.2018.11.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
228 Matsuda T, Taniguchi F, Minato H, Nomura H, Tsuda T, Aikawa I. Successful resection of advanced pancreatic tail cancer after neoadjuvant gemcitabine chemotherapy: report of a case. Surg Today 2006;36:754-7. [PMID: 16865525 DOI: 10.1007/s00595-006-3227-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
229 Mackenzie RP, McCollum AD. Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev Anticancer Ther. 2009;9:1473-1485. [PMID: 19828009 DOI: 10.1586/era.09.109] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
230 Rudloff U, Maker AV, Brennan MF, Allen PJ. Randomized Clinical Trials in Pancreatic Adenocarcinoma. Surgical Oncology Clinics of North America 2010;19:115-50. [DOI: 10.1016/j.soc.2009.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
231 Zhang H, Kellett C, Lambert P, Kim CA. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience. Clin Colorectal Cancer. 2018;17:e451-e456. [PMID: 29631907 DOI: 10.1016/j.clcc.2018.03.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
232 Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005;23:842-9. [PMID: 15681529 DOI: 10.1200/JCO.2005.03.170] [Cited by in Crossref: 128] [Cited by in F6Publishing: 34] [Article Influence: 7.5] [Reference Citation Analysis]
233 Lapointe R, Létourneau R, Steward W, Hawkins R, Batist G, Vincent M, Whittom R, Eatock M, Jolivet J, Moore M. Phase II study of troxacitabine in chemotherapy-naïve patients with advanced cancer of the pancreas. Annals of Oncology 2005;16:289-93. [DOI: 10.1093/annonc/mdi061] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
234 Chiaravalli M, Reni M, O'reilly EM. Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treatment Reviews 2017;60:32-43. [DOI: 10.1016/j.ctrv.2017.08.007] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 15.2] [Reference Citation Analysis]
235 Ducreux M, Boige V, Malka D. Emerging drugs in pancreatic cancer. Expert Opin Emerg Drugs. 2004;9:73-89. [PMID: 15155137 DOI: 10.1517/14728214.9.1.73] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
236 Bouché O. Les biothérapies ciblées en cancérologie digestive : une nouvelle ère dans la stratégie thérapeutique ? Gastroentérologie Clinique et Biologique 2005;29:495-500. [DOI: 10.1016/s0399-8320(05)82118-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
237 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
238 Mercalli A, Sordi V, Formicola R, Dandrea M, Beghelli S, Scarpa A, Di Carlo V, Reni M, Piemonti L. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. Br J Cancer 2007;96:1358-67. [PMID: 17426706 DOI: 10.1038/sj.bjc.6603726] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
239 Mahalingam D, Giles F. Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opin Ther Targets. 2008;12:1389-1401. [PMID: 18851695 DOI: 10.1517/14728222.12.11.1389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
240 Takeda Y, Nakamori S, Eguchi H, Kobayashi S, Marubashi S, Tanemura M, Konishi K, Yoshioka Y, Umeshita K, Mori M. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. Jpn J Clin Oncol. 2014;44:1172-1180. [PMID: 25425728 DOI: 10.1093/jjco/hyu143] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
241 Rivera F, López-Tarruella S, Vega-Villegas ME, Salcedo M. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 2009;35:335-339. [PMID: 19131170 DOI: 10.1016/j.ctrv.2008.11.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 5.6] [Reference Citation Analysis]
242 Katz MH, Fleming JB, Lee JE, Pisters PW. Current status of adjuvant therapy for pancreatic cancer. Oncologist. 2010;15:1205-1213. [PMID: 21045189 DOI: 10.1634/theoncologist.2010-0121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
243 Berlin JD, Rothenberg ML. Chemotherapeutic advances in pancreatic cancer. Curr Oncol Rep. 2003;5:219-226. [PMID: 12667419 DOI: 10.1007/s11912-003-0113-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
244 Tellman TV, Cruz LA, Grindel BJ, Farach-Carson MC. Cleavage of the Perlecan-Semaphorin 3A-Plexin A1-Neuropilin-1 (PSPN) Complex by Matrix Metalloproteinase 7/Matrilysin Triggers Prostate Cancer Cell Dyscohesion and Migration. Int J Mol Sci 2021;22:3218. [PMID: 33809984 DOI: 10.3390/ijms22063218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Endlicher E, Troppmann M, Kullmann A, Golder S, Herold T, Herfarth H, Grossmann J, Schlottmann K, Kullmann F. Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study. Oncology. 2007;72:279-284. [PMID: 18187949 DOI: 10.1159/000113039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
246 Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:801-808. [PMID: 17379445 DOI: 10.1016/j.ijrobp.2006.12.053] [Cited by in Crossref: 159] [Cited by in F6Publishing: 138] [Article Influence: 10.6] [Reference Citation Analysis]
247 Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005;6:369-376. [PMID: 15925814 DOI: 10.1016/s1470-2045(05)70175-3] [Cited by in Crossref: 195] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
248 Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol 2009;2:13. [PMID: 19291303 DOI: 10.1186/1756-8722-2-13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
249 da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer. 2010;116:5599-5607. [PMID: 20824720 DOI: 10.1002/cncr.25393] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 9.3] [Reference Citation Analysis]
250 Arshad A, Al-Leswas D, Al-Taan O, Stephenson J, Metcalfe M, Steward WP, Dennison AR. Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer. Am J Clin Oncol 2013;36:411-4. [PMID: 21436672 DOI: 10.1097/COC.0b013e3182124216] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
251 Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, Yip D. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Crit Rev Oncol Hematol. 2015;96:483-497. [PMID: 26481952 DOI: 10.1016/j.critrevonc.2015.07.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
252 Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 2008;57:1-17. [PMID: 17661033 DOI: 10.1007/s00262-007-0365-5] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 7.5] [Reference Citation Analysis]
253 Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL. A phase III trial of pemetrexed plus gemcitabine vs gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639-1645. [PMID: 16087696 DOI: 10.1093/annonc/mdi309] [Cited by in Crossref: 231] [Cited by in F6Publishing: 217] [Article Influence: 13.6] [Reference Citation Analysis]
254 Buecher B, Blottière HM. Nouvelles approches pharmacologiques de traitement des cancers. Gastroentérologie Clinique et Biologique 2004;28:167-80. [DOI: 10.1016/s0399-8320(04)94872-5] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
255 Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 2010; 16(6): 673-682 [PMID: 20135714 DOI: 10.3748/wjg.v16.i6.673] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
256 Bachet JB, Mitry E, Lièvre A, Lepère C, Vaillant JN, Declety G, Parlier H, Emile JF, Julié C, Rougier P. Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. Gastroenterol Clin Biol. 2009;33:1036-1044. [PMID: 19758779 DOI: 10.1016/j.gcb.2009.03.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
257 Harati R, Hafezi S, Mabondzo A, Tlili A. Silencing miR-202-3p increases MMP-1 and promotes a brain invasive phenotype in metastatic breast cancer cells. PLoS One 2020;15:e0239292. [PMID: 33002044 DOI: 10.1371/journal.pone.0239292] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
258 Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011;68:3853-3868. [PMID: 21744247 DOI: 10.1007/s00018-011-0763-x] [Cited by in Crossref: 172] [Cited by in F6Publishing: 160] [Article Influence: 15.6] [Reference Citation Analysis]
259 Laquente B, Macarulla T, Bugés C, Martín M, García C, Pericay C, Merino S, Visa L, Martín T, Pedraza M, Carnero B, Guardeño R, Verdaguer H, Mut A, Vilanova D, García A. Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice. BMC Palliat Care 2020;19:103. [PMID: 32650765 DOI: 10.1186/s12904-020-00610-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
260 Steins M, Thomas M, Geißler M. Erlotinib. Recent Results Cancer Res 2018;211:1-17. [PMID: 30069756 DOI: 10.1007/978-3-319-91442-8_1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
261 Spratlin JL, Mulder KE. Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. Int J Mol Sci 2011;12:5895-907. [PMID: 22016635 DOI: 10.3390/ijms12095895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
262 Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J Gastroenterol 2014; 20(37): 13343-13368 [PMID: 25309069 DOI: 10.3748/wjg.v20.i37.13343] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
263 Yip D, Goldstein D. Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer. Cancer Treat Rev. 2005;31:236-241. [PMID: 15882933 DOI: 10.1016/j.ctrv.2005.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
264 Zalatnai A. Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma. Cancer Treatment Reviews 2007;33:289-98. [DOI: 10.1016/j.ctrv.2006.12.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
265 Simpson S, Dunning M, de Brot S, Alibhai A, Bailey C, Woodcock CL, Mestas M, Akhtar S, Jeyapalan JN, Lothion-Roy J, Emes RD, Allegrucci C, Rizvanov AA, Mongan NP, Rutland CS. Molecular Characterisation of Canine Osteosarcoma in High Risk Breeds. Cancers (Basel) 2020;12:E2405. [PMID: 32854182 DOI: 10.3390/cancers12092405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
266 Bendell J, Goldberg RM. Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Curr Opin Oncol 2007;19:390-5. [PMID: 17545806 DOI: 10.1097/CCO.0b013e32816f76f0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
267 Danovi SA, Wong HH, Lemoine NR. Targeted therapies for pancreatic cancer. Br Med Bull. 2008;87:97-130. [PMID: 18753179 DOI: 10.1093/bmb/ldn027] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
268 Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266-4276. [PMID: 22896693 DOI: 10.1158/1078-0432.ccr-11-3114] [Cited by in Crossref: 711] [Cited by in F6Publishing: 486] [Article Influence: 79.0] [Reference Citation Analysis]
269 Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006;3:CD002093. [PMID: 16855985 DOI: 10.1002/14651858.cd002093.pub2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
270 Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2007;59:361-7. [PMID: 16807732 DOI: 10.1007/s00280-006-0277-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
271 Saad ED, Hoff PM. Molecular-Targeted Agents in Pancreatic Cancer. Cancer Control 2004;11:32-8. [DOI: 10.1177/107327480401100105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
272 Adhikari N, Amin SA, Jha T. Collagenases and gelatinases and their inhibitors as anticancer agents. Cancer-Leading Proteases. Elsevier; 2020. pp. 265-94. [DOI: 10.1016/b978-0-12-818168-3.00010-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P, Tagliaferri P. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013;49:593-603. [PMID: 22989511 DOI: 10.1016/j.ejca.2012.08.019] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 7.6] [Reference Citation Analysis]
274 Patten LC, Berger DH. Role of Proteases in Pancreatic Carcinoma. World J Surg 2005;29:258-63. [DOI: 10.1007/s00268-004-7816-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
275 Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 2006;94:1107-15. [PMID: 16622436 DOI: 10.1038/sj.bjc.6603058] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
276 Peixoto RD, Ho M, Renouf DJ, Lim HJ, Gill S, Ruan JY, Cheung WY. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. Am J Clin Oncol. 2015; Apr 1; Epub ahead of print. [PMID: 25844823 DOI: 10.1097/coc.0000000000000193] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
277 Bachmeier BE, Iancu CM, Jochum M, Nerlich AG. Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach. Expert Rev Anticancer Ther. 2005;5:149-163. [PMID: 15757447 DOI: 10.1586/14737140.5.1.149] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
278 Maneshi P, Mason J, Dongre M, Öhlund D. Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits. Front Cell Dev Biol 2021;9:787485. [PMID: 34901028 DOI: 10.3389/fcell.2021.787485] [Reference Citation Analysis]
279 Mukherjee S, Hudson E, Reza S, Thomas M, Crosby T, Maughan T. Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer. Clin Oncol (R Coll Radiol) 2008;20:535-40. [PMID: 18346883 DOI: 10.1016/j.clon.2008.02.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
280 Löhr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Fölsch UR, Jäger D, Osinsky D, Prausova J. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. 2012;23:1214-1222. [PMID: 21896540 DOI: 10.1093/annonc/mdr379] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
281 Li J, Podoltsev N, Saif MW. Management of advanced pancreatic cancer. Expert Review of Clinical Pharmacology 2014;2:527-41. [DOI: 10.1586/ecp.09.30] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
282 Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, Oh DY, Liu Y, Redhu S, Steplewski K. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. Eur J Cancer. 2014;50:2072-2081. [PMID: 24915778 DOI: 10.1016/j.ejca.2014.04.024] [Cited by in Crossref: 167] [Cited by in F6Publishing: 163] [Article Influence: 20.9] [Reference Citation Analysis]
283 Sahin IH, Iacobuzio-Donahue CA, O’Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets. 2016;20:341-359. [PMID: 26439702 DOI: 10.1517/14728222.2016.1094057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
284 Friberg G, Kindler HL. Chemotherapy for advanced pancreatic cancer: Past, present, and future. Curr Oncol Rep 2005;7:186-95. [DOI: 10.1007/s11912-005-0072-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
285 Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006;168:962-972. [PMID: 16507911 DOI: 10.2353/ajpath.2006.050570] [Cited by in Crossref: 143] [Cited by in F6Publishing: 128] [Article Influence: 8.9] [Reference Citation Analysis]
286 Conroy T, Paillot B, François E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23:1228-1236. [PMID: 15718320 DOI: 10.1200/jco.2005.06.050] [Cited by in Crossref: 154] [Cited by in F6Publishing: 56] [Article Influence: 9.1] [Reference Citation Analysis]
287 Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Gastroenterol Rep. 2004;6:119-125. [PMID: 15191689 DOI: 10.1007/s11894-004-0038-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
288 Colloca G, Venturino A, Guarneri D. Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer. Clin Colorectal Cancer 2016;15:264-76. [PMID: 26776098 DOI: 10.1016/j.clcc.2015.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
289 Medina C, Santana A, Quintero E, Radomski M, Guarner F. Metaloproteinasas de matriz en enfermedades del tracto gastrointestinal. Gastroenterología y Hepatología 2004;27:491-7. [DOI: 10.1016/s0210-5705(03)70509-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
290 Collins DC, Morris PG. Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy. Expert Opinion on Pharmacotherapy 2015;16:851-61. [DOI: 10.1517/14656566.2015.1024654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
291 Barillari G, Monini P, Sgadari C, Ensoli B. The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies. Int J Mol Sci 2018;19:E1418. [PMID: 29747434 DOI: 10.3390/ijms19051418] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
292 Hochster HS. The Role of Pemetrexed in the Treatment of Gastrointestinal Malignancy. Clinical Colorectal Cancer 2004;4:190-5. [DOI: 10.3816/ccc.2004.n.019] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
293 Kim CA, Chu QSC, Fassbender K, Ghosh S, Spratlin JL. Predictive Impact of Clinical Benefit in Chemotherapy-treated Advanced Pancreatic Cancer Patients in Northern Alberta. Am J Clin Oncol 2018;41:867-73. [PMID: 28368922 DOI: 10.1097/COC.0000000000000385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
294 Mishra G, Liu TF, Frankel AE. Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells. Expert Opinion on Biological Therapy 2005;3:1173-80. [DOI: 10.1517/14712598.3.7.1173] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
295 Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer 2014;14:471. [PMID: 24972449 DOI: 10.1186/1471-2407-14-471] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
296 Fields GB. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases. Front Immunol 2019;10:1278. [PMID: 31214203 DOI: 10.3389/fimmu.2019.01278] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
297 Saif MW, Karapanagiotou L, Syrigos K. Genetic alterations in pancreatic cancer. World J Gastroenterol 2007; 13(33): 4423-4430 [PMID: 17724796 DOI: 10.3748/wjg.v13.i33.4423] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
298 Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G. Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol. 2010;33:461-464. [PMID: 20142727 DOI: 10.1097/coc.0b013e3181b4e3b0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
299 Mountzios G, Syrigos KN. A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer. Drug Saf 2011;34:175-86. [PMID: 21332242 DOI: 10.2165/11586540-000000000-00000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
300 Lawrence B, Findlay M. Systemic therapy for metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol 2010;2:85-106. [PMID: 21789129 DOI: 10.1177/1758834009357188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
301 Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PLoS One. 2012;7:e38477. [PMID: 22723862 DOI: 10.1371/journal.pone.0038477] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
302 Lopes G, Rocha Lima CM. Docetaxel in the management of advanced pancreatic cancer. Semin Oncol 2005;32:S10-23. [PMID: 16015551 DOI: 10.1053/j.seminoncol.2005.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
303 Strimpakos AS, Syrigos KN, Saif MW. The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver 2010;4:433-49. [PMID: 21253292 DOI: 10.5009/gnl.2010.4.4.433] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
304 Singh D, Upadhyay G, Srivastava RK, Shankar S. Recent advances in pancreatic cancer: biology, treatment, and prevention. Biochim Biophys Acta 2015;1856:13-27. [PMID: 25977074 DOI: 10.1016/j.bbcan.2015.04.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
305 Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009;6:412-22. [PMID: 19506583 DOI: 10.1038/nrgastro.2009.89] [Cited by in Crossref: 141] [Cited by in F6Publishing: 135] [Article Influence: 10.8] [Reference Citation Analysis]
306 Chen Y, Peng S, Cen H, Lin Y, Huang C, Chen Y, Shan H, Su Y, Zeng L. MicroRNA hsa-miR-623 directly suppresses MMP1 and attenuates IL-8-induced metastasis in pancreatic cancer. Int J Oncol 2019;55:142-56. [PMID: 31115512 DOI: 10.3892/ijo.2019.4803] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
307 Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516. [PMID: 15908661 DOI: 10.1200/jco.2005.06.023] [Cited by in Crossref: 664] [Cited by in F6Publishing: 304] [Article Influence: 39.1] [Reference Citation Analysis]
308 Kundranda M, Kachaamy T. Promising new therapies in advanced pancreatic adenocarcinomas. Future Oncol 2014;10:2629-41. [PMID: 25531049 DOI: 10.2217/fon.14.197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
309 Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018;3:CD011044. [PMID: 29557103 DOI: 10.1002/14651858.CD011044.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
310 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets. 2012;13:811-828. [PMID: 22458528 DOI: 10.1016/j.pestbp.2011.02.012.investigations] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
311 Prat A, Baselga J. [Biologic therapy: current and future applications in oncology]. Med Clin (Barc) 2007;129:184-93. [PMID: 17669336 DOI: 10.1157/13107796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
312 Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol. 2005;1:7-17. [PMID: 16555971 DOI: 10.1517/14796694.1.1.7] [Cited by in Crossref: 172] [Cited by in F6Publishing: 160] [Article Influence: 10.8] [Reference Citation Analysis]
313 Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316 [PMID: 26309356 DOI: 10.3748/wjg.v21.i31.9297] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 74] [Article Influence: 11.9] [Reference Citation Analysis]
314 Edwards JG, McLaren J, Jones JL, Waller DA, O'Byrne KJ. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 2003;88:1553-9. [PMID: 12771921 DOI: 10.1038/sj.bjc.6600920] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 2.8] [Reference Citation Analysis]
315 Kristensen A, Vagnildhaug OM, Grønberg BH, Kaasa S, Laird B, Solheim TS. Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. Crit Rev Oncol Hematol 2016;99:286-98. [PMID: 26819138 DOI: 10.1016/j.critrevonc.2016.01.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
316 Koido S, Homma S, Takahara A, Namiki Y, Tsukinaga S, Mitobe J, Odahara S, Yukawa T, Matsudaira H, Nagatsuma K. Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol. 2011;2011:267539. [PMID: 21922022 DOI: 10.1155/2011/267539] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
317 Chau I, Watkins D, Cunningham D. Gemcitabine and Its Combinations in the Treatment of Malignant Lymphoma. Clinical Lymphoma 2002;3:97-104. [DOI: 10.3816/clm.2002.n.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
318 Lideståhl A, Permert J, Linder S, Bylund H, Edsborg N, Lind P. Efficacy of systemic therapy in advanced pancreatic carcinoma. Acta Oncol 2006;45:136-43. [PMID: 16546858 DOI: 10.1080/02841860500537861] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
319 Sezgin C, Karabulut B, Uslu R, Sanli UA, Goksel G, Yuzer Y, Goker E. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scand J Gastroenterol. 2005;40:1486-1492. [PMID: 16293561 DOI: 10.1080/00365520510023819] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
320 Carneiro BA, Brand RE, Fine E, Knop RH, Khandekar JD, Uhlig W, Locker GY. Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma. Cancer Invest 2007;25:366-71. [PMID: 17661212 DOI: 10.1080/15368370701357957] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
321 Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol. 2014;5:280-295. [PMID: 25083302 DOI: 10.3978/j.issn.2078-6891.2014.030] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
322 Hamada T, Nakai Y, Isayama H, Yasunaga H, Matsui H, Takahara N, Mizuno S, Kogure H, Matsubara S, Yamamoto N, Tada M, Koike K. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. European Journal of Cancer 2016;65:11-20. [DOI: 10.1016/j.ejca.2016.05.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
323 Sullivan KM, Kozuch PS. Chemotherapy and Other Supportive Modalities in the Palliative Setting for Pancreatic Cancer. The Cancer Journal 2012;18:633-41. [DOI: 10.1097/ppo.0b013e318275896f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
324 Eckhardt SG, De Porre P, Smith D, Maurel J, Steward WP, Bouche O, van de Velde H, Michiels B, Bugat R. Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. J Pain Symptom Manage. 2009;37:135-143. [PMID: 18723314 DOI: 10.1016/j.jpainsymman.2008.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
325 Tang M, Chen J, Goldstein D, Links M, Lord S, Marschner I, Simes RJ, Lee CK. Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. Pancreas 2019;48:1274-84. [PMID: 31688590 DOI: 10.1097/MPA.0000000000001429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 Li W, Saji S, Sato F, Noda M, Toi M. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects. Int J Biol Markers 2013;28:117-30. [PMID: 23787494 DOI: 10.5301/jbm.5000026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
327 Michalczyk K, Cymbaluk-Płoska A. Metalloproteinases in Endometrial Cancer-Are They Worth Measuring? Int J Mol Sci 2021;22:12472. [PMID: 34830354 DOI: 10.3390/ijms222212472] [Reference Citation Analysis]
328 Ch’ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. J Gastroenterol Hepatol. 2006;21:874-879. [PMID: 16704539 DOI: 10.1111/j.1440-1746.2005.04022.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
329 Nicolella D, Maione P, Gridelli C. Targeted therapies: focus on a new strategy for gastrointestinal tumors. Crit Rev Oncol Hematol. 2003;47:261-271. [PMID: 12962900 DOI: 10.1016/s1040-8428(03)00057-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
330 Obeid KM, Venugopal AA. Gemcitabine-associated "pseudocellulitis" and "pseudosepsis": a case report and review of the literature. Am J Ther 2013;20:118-20. [PMID: 21768869 DOI: 10.1097/MJT.0b013e3182204ffe] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
331 Tabernero J, Macarulla T. Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J Clin Oncol. 2009;27:5487-5491. [PMID: 19858387 DOI: 10.1200/jco.2009.23.3098] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
332 Wu Y, Zhang C, Jiang K, Werner J, Bazhin AV, D'Haese JG. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. Front Oncol 2020;10:621937. [PMID: 33520728 DOI: 10.3389/fonc.2020.621937] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
333 Chua Y, Zalcberg J. Pancreatic cancer—is the wall crumbling? Annals of Oncology 2008;19:1224-30. [DOI: 10.1093/annonc/mdn063] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
334 Nomura Y, Takasaki K, Tada M, Yoshimoto M, Ishida H, Murata N, Kubota S. Pro-MMP-9 is associated with poor prognosis in gastric cancer. Scandinavian Journal of Gastroenterology 2009;42:1070-2. [DOI: 10.1080/00365520701435881] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
335 Hariharan S, Gustafson D, Holden S, Mcconkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'bryant C, Baron A, Gallemann D, Colevas D, Eckhardt S. Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Annals of Oncology 2007;18:1400-7. [DOI: 10.1093/annonc/mdm140] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 5.2] [Reference Citation Analysis]
336 Rucki AA, Zheng L. Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies. World J Gastroenterol 2014; 20(9): 2237-2246 [PMID: 24605023 DOI: 10.3748/wjg.v20.i9.2237] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
337 Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J Clin Oncol. 2010;28:3611-3616. [PMID: 20606094 DOI: 10.1200/JCO.2009.25.8285] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
338 Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. J Exp Clin Cancer Res 2013;32:12. [PMID: 23497499 DOI: 10.1186/1756-9966-32-12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
339 Rocha Lima CM, Flores AM. Gemcitabine doublets in advanced pancreatic cancer: should we move on? J Clin Oncol 2006;24:327-9. [PMID: 16344312 DOI: 10.1200/JCO.2005.03.8315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
340 Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer. Head Neck 2006;28:639-48. [PMID: 16470875 DOI: 10.1002/hed.20365] [Cited by in Crossref: 108] [Cited by in F6Publishing: 98] [Article Influence: 6.8] [Reference Citation Analysis]
341 Fields GB. The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma. Cells 2019;8:E984. [PMID: 31461880 DOI: 10.3390/cells8090984] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 25.3] [Reference Citation Analysis]
342 Haller DG. Chemotherapy for advanced pancreatic cancer. International Journal of Radiation Oncology*Biology*Physics 2003;56:16-23. [DOI: 10.1016/s0360-3016(03)00448-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
343 Tjomsland V, Pomianowska E, Aasrum M, Sandnes D, Verbeke CS, Gladhaug IP. Profile of MMP and TIMP Expression in Human Pancreatic Stellate Cells: Regulation by IL-1α and TGFβ and Implications for Migration of Pancreatic Cancer Cells. Neoplasia 2016;18:447-56. [PMID: 27435927 DOI: 10.1016/j.neo.2016.06.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
344 Awasthi N, Schwarz MA, Schwarz RE. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy. Cancer Chemother Pharmacol 2011;68:571-82. [PMID: 21110024 DOI: 10.1007/s00280-010-1514-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
345 Dekoj T, Lee S, Desai S, Trevino J, Babcock TA, Helton WS, Espat NJ. G2/M cell-cycle arrest and apoptosis by n-3 fatty acids in a pancreatic cancer model. J Surg Res. 2007;139:106-112. [PMID: 17291531 DOI: 10.1016/j.jss.2006.10.024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
346 Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y, Zhang FC. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 2011;4:11. [PMID: 21439076 DOI: 10.1186/1756-8722-4-11] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
347 Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ, Munshi HG. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res 2011;71:1019-28. [PMID: 21148071 DOI: 10.1158/0008-5472.CAN-10-1855] [Cited by in Crossref: 110] [Cited by in F6Publishing: 75] [Article Influence: 9.2] [Reference Citation Analysis]
348 Antczak C, Radu C, Djaballah H. A profiling platform for the identification of selective metalloprotease inhibitors. J Biomol Screen 2008;13:285-94. [PMID: 18349423 DOI: 10.1177/1087057108315877] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
349 Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-4958 [PMID: 23002368 DOI: 10.3748/wjg.v18.i35.4944] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
350 Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005;68:171-178. [PMID: 16006754 DOI: 10.1159/000086771] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 4.7] [Reference Citation Analysis]
351 Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Genes Dis. 2015;2:133-143. [PMID: 26114155 DOI: 10.1016/j.gendis.2015.01.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 10.9] [Reference Citation Analysis]
352 Zhang Z, Ji S, Zhang B, Liu J, Qin Y, Xu J, Yu X. Role of angiogenesis in pancreatic cancer biology and therapy. Biomed Pharmacother 2018;108:1135-40. [PMID: 30372814 DOI: 10.1016/j.biopha.2018.09.136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
353 Hidalgo M, Abad A, Aranda E, Díez L, Feliu J, Gómez C, Irigoyen A, López R, Rivera F, Rubio C, Sastre J, Tabernero J, Díaz-Rubio E. Consensus on the treatment of pancreatic cancer in Spain. Clin Transl Oncol 2009;11:290-301. [PMID: 19451062 DOI: 10.1007/s12094-009-0357-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
354 Diab M, Azmi A, Mohammad R, Philip PA. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opin Pharmacother 2019;20:535-46. [PMID: 30592647 DOI: 10.1080/14656566.2018.1561869] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
355 Milkiewicz M, Ispanovic E, Doyle JL, Haas TL. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol 2006;38:333-57. [PMID: 16309946 DOI: 10.1016/j.biocel.2005.10.006] [Cited by in Crossref: 103] [Cited by in F6Publishing: 86] [Article Influence: 6.1] [Reference Citation Analysis]
356 Yee NS. Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype. Adv Exp Med Biol 2013;779:91-143. [PMID: 23288637 DOI: 10.1007/978-1-4614-6176-0_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]